Twelve-month extension study to evaluate the long-term durability of RP-G28 on a subset of Phase 2b/3 clinical trial patients with lactose intolerene
Latest Information Update: 19 Nov 2016
At a glance
- Drugs RP G28 (Primary)
- Indications Lactose intolerance
- Focus Therapeutic Use
- Sponsors Ritter Pharmaceuticals
- 19 Nov 2016 New trial record